Researchers Explore APOBECs to Combat Cancer Treatment Challenges

A group of researchers at the University of Texas Health Science Center at San Antonio is examining the role of enzymes known as APOBECs in cancer treatment. On April 7, 2024, Dr. Reuben Harris, chair of the Department of Biochemistry and Structural Biology, highlighted how these enzymes, though beneficial in protecting against viruses, can become detrimental when dysregulated in cancer patients.

APOBECs, or apolipoprotein B mRNA-editing enzymes, typically function as a defense mechanism against invading viruses. Dr. Harris explained that while they play a protective role, in cancer scenarios, they can inadvertently inflict harm on our own DNA. “In cancer, the good guys can become villains that do catastrophic damage,” he remarked.

The research team proposes that during standard treatment procedures, such as surgical resection of tumors, there exists a critical opportunity to mitigate the adverse effects caused by APOBEC enzymes. Following the removal of an APOBEC-positive tumor, halting these enzymes could potentially curb the risk of cancer recurrence, spread, or mutation, which often leads to resistance against medication.

“Our goal is to stop APOBECs from doing any more damage,” Dr. Harris stated. He emphasized that by addressing this issue, they could significantly reduce the likelihood of adverse events related to cancer treatment. This innovative approach presents a promising avenue for improving patient outcomes and reducing the complexities associated with cancer treatment.

The collaboration between TPR and the University of Texas Health Science Center aims to shed light on how scientific advancements in San Antonio are reshaping medical practices globally. Through this initiative, the researchers hope to generate greater awareness and understanding of the potential implications of their findings on cancer therapies.

As this research progresses, the implications for patients could be transformative. By effectively managing the activity of APOBECs during treatment, healthcare providers may enhance the efficacy of cancer therapies, leading to improved survival rates and quality of life for patients battling this challenging disease.